The cluster shows conviction from active managers post-earnings, but the IMpactMF trial discontinuation removes a key pipeline catalyst, increasing reliance on LR-MDS. Monitor next quarter's 13F for whether these adds persist or reverse, and watch for any pipeline updates.
Drug in focus
GERN drug pipeline →RYTELO
● Neutral Named in this fund cluster- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available (first commercial launch in Q3 2024)
- Next catalyst
- None dated
What to watchWatch the Q3 2026 earnings release on Nov 4, 2026 (consensus ~$60.4M revenue). The key question is whether RYTELO's revenue growth trajectory can accelerate from the ~11% QoQ pace, which would validate the revenue ramp thesis behind the $4+ analyst targets. The 7.39 days-to-cover short interest adds a squeeze potential if results surprise positively, but the shareholder lawsuit and high short volume ratio suggest significant skepticism about the commercial ramp.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $0.9965entry
- T+1 · 7d ago −2.24%α −1.87% · $0.9742
- T+5 · 20h ago −5.48%α −3.79% · $0.9419
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Eight institutional investors added $3.6M in GERN positions during Q3 2026, while two trimmed $509K, for net buying of $3.1M. The cluster is dominated by active asset managers and follows Q3 earnings that showed 27% RYTELO revenue growth and a swing to net income, but also the discontinuation of the Phase 3 IMpactMF trial, which removed a key pipeline catalyst.
Key Financial Metrics
Institutional Positions
Net institutional flow: $3.1M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Candriam S.c.a. | ADD | +42.8% | $9.9M | $2.7M |
| Creative Planning | DOUBLED | +133.3% | $476.0K | $264.0K |
| Alps Advisors | ADD | +30.7% | $1.0M | $214.0K |
| Barclays | DOUBLED | +102.6% | $287.0K | $140.0K |
| Simplex Trading | ADD | +97.1% | $274.0K | $129.0K |
| Lpl Financial | ADD | +45.8% | $327.0K | $94.0K |
| Principal Financial Group | ADD | +53.6% | $81.0K | $26.0K |
| Pnc Financial Services Group | ADD | +46.8% | $6.0K | $2.0K |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citigroup | TRIM | -33.5% | $1.1M | -$381.0K |
| Proshare Advisors | TRIM | -50.9% | $241.0K | -$128.0K |
Key Facts
- 8 institutional buyers added $3.6M in net new positions during Q3 2026
- 2 institutional sellers trimmed $509K in positions
- Largest buyer Candriam S.c.a. added $2.7M (+42.8% shares to 7.98M shares)
- No open-market insider buying in the same window (confluence score 32/100)
- Q3 2026 earnings showed RYTELO revenue of $60.1M (+27% YoY) and net income of $1.4M vs a net loss of $18.4M a year ago
- Phase 3 IMpactMF trial in myelofibrosis was discontinued after DMC recommendation
Financial Impact
8 institutions accumulated $3.6M in new positions while 2 reduced holdings by $509K; net institutional buying of $3.1M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Phase 3 IMpactMF trial discontinuation eliminates a key pipeline catalyst
- No insider buying corroboration weakens the conviction signal
- Cluster is relatively small in dollar terms ($3.6M net) vs $612M market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-GERN-2026-Q3 |
Track record
11 reports on GERN
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $0.9742 settles Nov 17
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Viewing Entry $0.9965 to $0.9419 ▼ −5.48% −3.79% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $1.08 to $1.02 ▼ −5.56% −4.64% vs SPY
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $0.9462 to $0.9501 ▼ −0.41% −5.14% vs SPY
- Oct 19, 202628d ago Press Release Neutral 2/10 Entry $1.24 to $1.16 ▼ −6.85% −6.88% vs SPY
- Sep 18, 20268w ago Press Release Neutral 2/10 Entry $1.30 to $1.25 ▼ −3.85% −2.83% vs SPY
- Apr 22, 202629w ago Press Release Neutral 1/10 Entry $1.55 to $1.52 ▼ −2.26% −2.31% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $1.71 to $1.69 ▼ −1.17% −4.69% vs SPY
- Mar 30, 202633w ago Court Ruling Neutral 2/10 Entry $1.41 to $1.74 ▲ +23.40% +19.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers